

**HPBMC Human Peripheral Blood Mononuclear Cells, cryopreserved**  
**Cell Specification // Certificate of Analysis**

Lot HPBMC 210128

Batch Release: Feb 18, 2021

Freshly isolated human peripheral blood mononuclear cells (PBMC) from healthy donors were purified by density gradient centrifugation using Ficoll®.

Cryopreserved cells were thawed. Cell number and viability were determined by Trypan blue exclusion staining. Subpopulations were identified by flow cytometry.

**Donor demographics and lot specific information**

Gender	Age	Ethnicity	Anticoagulant
Female	22 years	Caucasian	CPD (Citrate-Phosphate-Dextrose)

**Serology Testing**

Donor has been screened and tested negative for:

- Hepatitis B (HBV, HBsAg)
- Hepatitis C (HCV, anti-HCV)
- Human Immunodeficiency Virus (HIV-1/anti-HIV-1/2)
- Parvo B19
- Syphilis/Lues

**Cryopreservation:**

Date: Jan 28, 2021

Amount per vial:  $10.0 \times 10^6$  cells

**Thawing:** n=2

Post-thaw viability:  $85.2 \pm 2.8 \%$

Post-thaw yield per vial:  $5.1 \pm 0.5 \times 10^6$  cells


Recovery:  $50.7 \pm 4.7 \%$

**Analysis of PBMC subpopulations by flow cytometry:**

**Surface Marker Summary**

CD19 <sup>+</sup> B cells	CD3 <sup>+</sup> T cells	CD3 <sup>+</sup> CD4 <sup>+</sup> T cells	CD3 <sup>+</sup> CD8 <sup>+</sup> T cells	CD56 <sup>+</sup> NK cells	CD14 <sup>+</sup> Monocytes
7.2 %	82.0 %	53.0 %	25.2 %	9.3 %	15.7 %

## Flow cytometry analysis



**Store at -150 °C or in the vapour phase of LN<sub>2</sub>**

**This product should be considered as potential biohazard. Only intended for *in vitro* use. Not intended for therapeutic use.**

**Note:** Yield, viability and recovery were performed at PRIMACYT using PRIMACYT's manual for thawing of primary cryopreserved PMBCs.

Issued by: A. Ullrich

Verified by: T. Krimmling